Advice

Following a full submission considered under the orphan equivalent process:

pertuzumab (Perjeta®) is not recommended for use within NHSScotland.

Indication under review: for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.

The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease-free survival in patients with HER2-positive early breast cancer at high risk of recurrence. Overall survival data are immature.

The submitting company did not present a sufficiently robust clinical or economic analysis to gain acceptance by SMC.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Medicine details

Medicine name:
pertuzumab (Perjeta)
SMC ID:
SMC2197
Indication:

In combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC) at high risk of recurrence.

Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Not recommended
Date advice published
07 October 2019